chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Application Site reaction: cellulitis; induration - Information has been received from a health professional concerning a 37 year old caucasian female patient with a history of asthma who on 30 Aug 2000 was vaccinated SC on the right with a third dose of measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live second generation lot #629535/1507J.  On 31 Aug 2000 the patient developed a red spot for one week and was treated with ibuprofen.  On 11 sep 2000 the patient was seen by a  physician for increased redness and swelling.  It was noted that there was a 55mm induration.  There were no nodes in arm pit.  The diagnosis was local reaction with questionable early celluitis.  The patient was given a tetanus booster, cephalexin keflex mg qid x 7 days and hydrocortisone valerate westocort cream.
Swollen, redness, warm to touch on backside of arm. Started 10/13/17 approximately 2 days after receiving vaccine.
Pt recv vax on 3/29/99; on 3/30/99 pt exp swelling/ erythema of vax site, inc pain of fibromyalgia
pt recv vax 6AUG98 & 19AUG98 pt devel low grade fever & refusal to walk & went on to devel a monarticular arthritis of rt knee;pt hosp;aspiration of joint revealed sterile purulent fluid w/24,000WBC about 85% polys;
Post vax, the pt presented with progressive confusion, crying spells, and social withdrawal. Three months after symptom onset, he developed intermittent dystonic posturing of the left arm and leg. Initial neurological exam was significant for dysarthria and myoclonus of the left arm and leg. During the fourth month of illness, the pt developed hyperreflexia, and extensor plantar responses. By the fifth month, the myoclonus ceased. He became unresponsive, mute, and displayed intermittent hyperreflexia and tachycardia suggesting autonomic dysfunction. He expired six months after the onset of symptoms. An autopsy was refused. The cause of death was subacute sclerosing panencephalitis. Information about this case is described in an unpublished manuscript entitled "Subacute sclerosing panencephalitis in US born adult".
Patient given flu & pneumonia vaccine on 8/23/12, on 8/26/12 pt states his arm became swollen, red & inflamed. Ran fever of 102 degrees. Went to MD 8/27, was told may be infected. Pt was given CLEOCIN and Doxycycline. No fever today 8/27/12.
Patient stated to pharmacist on 12/29/2017 that she had been having pain under her left armpit and on her left shoulder since her vaccination. She has trouble trying to sleep on that shoulder. She states the pain is from the tip of the left shoulder down, and that it is only in certain positions. She states it hurts to lift certain things with the left arm. I advised her that if it continues she needs to contact her physician and schedule a visit with him so he can evaluate what is happening.
I?m experiencing severe skin rash all over my body. Started after the 2nd vaccine dose. I have seen different specialties including  Dermatologist, Allergy OBGYN and family physicians, they don?t know what caused this, and the symptoms doesn?t belong to any specific skin reaction. Also, I have missed my period for the last 3 months. I had noticed a few blood  spots  (light period) two months ago. All blood test is normal, but I?m still experiencing rash.
This case was reported by a physician via sales rep and described the occurrence of tingling of extremity in a 17-year-old female patient who received BEXSERO (batch number 16D401, expiry date 9th February 2019) for prophylaxis. Co-suspect products included FLULAVAL QUADRIVALENT 2017-2018 season) (batch number 5LR3F, expiry date 30th June 2018) for prophylaxis. On 17th November 2017, the patient received BEXSERO (intramuscular) .5 ml and FLULAVAL QUADRIVALENT 2017-2018 season (intramuscular) .5 ml. On 17th November 2017, less than a day after receiving BEXSERO and FLULAVAL QUADRIVALENT 2017-2018 season, the patient experienced tingling of extremity and pain. On an unknown date, the outcome of the tingling of extremity and pain were recovered/resolved. It was unknown if the reporter considered the tingling of extremity and pain to be related to BEXSERO and FLULAVAL QUADRIVALENT 2017-2018 season. Additional details were reported as follows: The patient received BEXSERO on the right arm and FLULAVAL QUADRIVALENT 2017-2018 season on the left arm. The physician reported that the patient went to the emergency room and was discharged home.
Weak; Chills; Feeling nauseous; Headache; Injection site area was sore; Couldnot sleep; This spontaneous case was reported by a patient and describes the occurrence of INSOMNIA (Couldnot sleep), ASTHENIA (Weak), CHILLS (Chills), NAUSEA (Feeling nauseous) and HEADACHE (Headache) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 25-Jan-2021 at 9:00 AM, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Jan-2021, the patient experienced INSOMNIA (Couldnot sleep) and VACCINATION SITE PAIN (Injection site area was sore). On 26-Jan-2021 at 2:00 AM, the patient experienced ASTHENIA (Weak), CHILLS (Chills), NAUSEA (Feeling nauseous) and HEADACHE (Headache). On 27-Jan-2021, INSOMNIA (Couldnot sleep), ASTHENIA (Weak), CHILLS (Chills), NAUSEA (Feeling nauseous), HEADACHE (Headache) and VACCINATION SITE PAIN (Injection site area was sore) had resolved.            Treatment and concomitant medications were not provided by reporter.
pt recv vax 3JUN98 & devel rash;dx erythema nodosum;pt seen by MD-dermatology;
October 2006 had to rush my son to hospital for vomiting profusely and diarrhea he continued to have various bowel and abdominal problems requiring doctor visits off and on up to 02/28/07  with his current doctor when his symptoms were abdominal pain so bad he would not stop crying-his feces was mucusy with yellow-pink coloration and this doctor said if it continues he will have him get an xray of his bowels/abdomin-today his feces is dark green and watery. Friday 03/09/07 he will see his doctor again for this. 04/25/07-received office notes from PCP-patient seen in follow up on 11/9/06-no complaints. Subsequent visits documented bright yellow stool and crying at visit dated 2/27/07. DX: Colic.
Headache, Myalgia, FATIGUE, MUSCLE/JOINT PAIN, HEADACHE Narrative:
2 weeks after getting the Pfizer vaccine, her mensural cycle started and didn't stop HEAVY bleeding for 40 days. Blood loss caused weakness and hormonal imbalance for the whole duration.
pain in the body; swelling; This is a spontaneous report from a non-contactable consumer (patient's mother). A female patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient experienced pain in the body and swelling on an unspecified date with outcome of unknown. The reporter reported that her daughter also presented side effects for the administration of the first dose of the vaccine, but these side effects were not present after the administration of the second dose of the immunization.  No follow-up attempts are possible; information on lot/batch cannot be obtained.
pt started experiencing tachycardia, dizziness, and itchiness within 2 minutes of receiving vaccine. pt reported symptoms 2 hours after receiving vaccine and was given 25 mg of diphenhydramine. pt was monitored every 60 minutes for changes.
Red and raised area of 3 cm after 2-3 min of being given. Doctor advised mother to give Benadryl and bring pt back to be seen if swelling worsens. Will follow up with mother with phone call.
7/20--7/26 Pt is a very pleasant 41 yo AAM PMHx HTN, obesity, CHF, OSA, presenting to the EC as a transfer for COVID pneumonia and hypoxia. Pt went to EC for fatigue and SOB. He was found to have significant HTN and SOB with O2 sats at 83%. He was transferred here for further work-up. Pt was given decadron and lasix in tandem with supplemental O2. He has been enjoying his usual health before getting COVID. He is vaccinated x 2. Was seen by ID and placed on remdesivir and dexamethasone. Eventually hypoxia resolved and patient was able to ambulate well without desaturation. Completed courses of remdesivir and dexamethasone inpatient. Discharged with instructions to follow up with primary care.
This initial spontaneous case was received from pharmacist on 07-Nov-2017, concerning a 11-year-old male child patient. The patient's medical history included ADHD and unspecified allergies (since an unspecified dates). The patient's concomitant medications included Clonidine, methylphenidate and ZYRTEC for an unknown indication. On 20-Oct-2017, the patient was administered with FLUCELVAX QIV (dose: 0.5 ml, route of administration: Intramuscular, anatomical location: deltoid, batch number: 195218, expiry date: Apr-2018). It was reported that, the patient had no problem at the time of vaccination. On an unspecified date, the patient had bruising, which started about a week ago (as reported on hospitalization), which was worsened and popped up all over the body. On 06-Nov-2017, the patient was admitted to the hospital. The patient's platelets were below to 1000 (unit and normal range no reported) and he was diagnosed with idiopathic thrombocytopenia and no other symptoms were reported. The haematologist stated that, it was not from the clonidine but a viral infection (unspecified) that the virus attached to the platelets. At the time of this report, the patient had not yet recovered from the events. The reporter assessed the events as serious due to hospitalization.
large hives over entire body. treated in emergency room with Claritin. Treated at Doctor's office with Prednisone pak.
DEMENTIA; This spontaneous report received from a consumer via a company representative via social media and concerned a female of unspecified age, race and ethnic origin. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported, 1 total administrated for covid-19 prophylaxis. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported.  On an unspecified date, a day after vaccination the patient experienced dementia and was in nursing home. The reported stated "Another friend of mine got it n her husband the day after she started getting dimensia she in a,nursing home k i dunno if its the reason but wst they said prayers for yall bc mayb onr day u c great again my left eye is no vision its called legally blind but it nit from the shot God bless all of yall effective by this". The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of dementia was not reported. This report was serious (Other Medically Important Condition). This case, from the same reporter is linked to 20221161446.; Sender's Comments: V0: 20221161477- dementia. The event has an unknown/unclear temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event. Therefore, the WHO Causality is considered indeterminate. The company causality is considered unassessable.
This case was reported by a pharmacist and described the occurrence of asthmatic reaction in a subject of unspecified age and gender who was vaccinated with FLUARIX (GlaxoSmithKline). On an unspecified date the subject received dose of FLUARIX (details unknown). At an unspecified time after vaccination with FLUARIX, the subject experienced asthmatic reaction. At the time of reporting the outcome of the event was unspecified. The pharmacist considered the event was possibly related to vaccination with FLUARIX. The pharmacist reported two subjects had asthmatic reactions to FLUARIX vaccinations (see case id A0999318A for details on the other subject). He did not have any further information. Follow up received from a nurse on 20 November 2012. Concurrent medical conditions included asthma, latex allergy, non smoker and non-drinker. Historic vaccination included seasonal influenza vaccine (non-gsk); non-GSK manufacturer; unknown; unknown given on 10 November 2010 and 8 November 2011 with "no reactions". On 24 October 2012, the subject received a dose of FLUARIX. The nurse reported a 43 year old female subject who experienced asthmatic reaction and bronchospasm less than a day after receiving a dose of FLUARIX (unknown details) on 24 October 2012 and was diagnosed with allergic reaction. The reporter stated that the adverse events had improved (date unknown). The reporter named the suspect product was FLUARIX and believed the event to be serious in nature due to the events being clinically significant or requiring intervention. Relevant diagnostic test results were on 24 October 2012: chest x-ray normal and complete CBC normal. On 26 October 2012, the subject had a blood test for reactivity to latex and eggs which was negative. The subject had a reactive skin test for latex allergy on an unknown date. The reporter indicated that the events could have been associated with the subject's medical history/ concurrent illness of asthma and latex allergy. The subject had received flu shots in the past. The immunization series was not discontinued or delayed.
Pain and swelling at the injection site; Intense itching at injection site; Swelling at the injection site; This case was reported by a nurse via call center representative and described the occurrence of injection site pain in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 1st July 2020, the patient received the 1st dose of Shingrix. In July 2020, less than a week after receiving Shingrix, the patient experienced injection site pain, injection site itching and injection site swelling. The patient was treated with non-drug therapy (Ice-Cold Compresses (Nos)) and hydrocortisone (Hydrocortisone Cream). On an unknown date, the outcome of the injection site pain, injection site itching and injection site swelling were recovered/resolved.   It was unknown if the reporter considered the injection site pain, injection site itching and injection site swelling to be related to Shingrix.  Additional case details were reported as follows: The patient experienced pain and swelling at the injection site after receiving Shingrix.  She also experienced intense itching at injection site.  The patient treated with ice compresses and icy hot. She also used hydrocortisone cream.  The reactions were intense for a day or two. By day 3, the reactions had begun to resolve. At time of report, reactions had resolved completely. The reporter consent to follow up.
SEVERE CHILLS; FEVER OF 101; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on 01-OCT-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On 01-OCT-2021, the patient experienced severe chills. On 01-OCT-2021, the patient experienced fever of 101. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the severe chills and fever of 101 was not reported. This report was non-serious.
pt's daughter said that her mom was experiencing  excruciating pain after getting the pneumovax on her left arm. The injection site was red and swollen. The pain was sharp and she couldn't move her arm. The daughter had already given her Tylenol 1gm  twice and icepack when she called. I then instructed her to  also give ibuprofen 200x3 too. I called back next day. The situation was about the same. I then called back on day #3. The situation had gotten slightly better but her arm still couldn't move.
Got COVID May2022; Got COVID May2022; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 41-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), in Jan2021 as dose 1, single (Lot number: EL3247), in Feb2021 as dose 2, single (Lot number: EL3247) and in Nov2021 as dose 3 (booster), single (Lot number: EW0217) at the age of 41 years for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: Penicillin" (unspecified if ongoing), notes: Known allergies: Penicillin. The patient's concomitant medications were not reported. Patient did not received any other vaccine in four weeks and did not have COVID prior to the COVID-19 vaccination. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 05May2022, outcome "recovered" (2022) and all described as "Got COVID May2022". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (05May2022) Positive, notes: COVID test type post vaccination: Nasal Swab. Therapeutic measures were not taken as a result of drug ineffective, covid-19.  No follow-up attempts are possible. No further information is expected.
vomiting/threw up multiple times; nauseas for 12 plus hours; had a fever ranging from 100.7 to 101.5; This is a spontaneous report from a contactable consumer (Parent of patient). A 13-years-old non pregnant female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot number: EW0178, Expiry date: not reported), via intramuscular route of administration in left arm on 03Jun2021 16:00 (at age of 13-years-old) as dose 2, single for covid-19 immunization in Doctor's office/Urgent Care. Medical history included thin basement membrane disease (Ongoing monitoring, no surgery), vitamin d deficiency and penicillin allergy. Concomitant medication(s) included colecalciferol (VITAMIN D [COLECALCIFEROL]) taken for vitamin d deficiency from 05May2021 and ongoing, colecalciferol (REPLESTA) taken for vitamin d deficiency from 05May2021 and ongoing. The patient previously took first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot number: EW0161, Expiration Date: Not reported), via intramuscular route of administration in left arm on 13May2021 16:00 (at age of 13-years-old) as dose 1, single for covid-19 immunization. The patient had not received any prior vaccinations. Prior to vaccination, the patient was not diagnosed with COVID-19 and post the vaccination, the patient was not tested for COVID-19. The caller reported that about 14 hours after the patient received the second covid shot (04Jun2021 at 04:00), the patient began vomiting. The patient threw up multiple times. The reporter estimated that the patient vomited about 4 times. The patient was nauseas for 12 plus hours and had a fever ranging from 100.7 to 101.5. The reporter assessed the events as non-serious. The patient underwent lab tests and procedures which included pyrexia: ranging from 100.7 to 101.5 on 04Jun2021. No relevant tests were performed. No therapeutic measures were taken in response to the events. The events recovered on an unspecified date in 2021 (patient had fully recovered).  Follow-up attempts are completed. No further information is expected.
RASH ALL OVER BODY AND FACE; NAUSEA; HEADACHE; FEVER; This spontaneous report received from a patient concerned a 25 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included non smoker, and other pre-existing medical conditions included patient had no known drug allergies. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805031, expiry: unknown) (vaccinated at right arm) dose was not reported, administered on 19-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 19-MAR-2021, the subject experienced nausea. On 19-MAR-2021, the subject experienced headache. On 19-MAR-2021, the subject experienced fever. On 25-MAR-2021, the subject experienced rash all over body and face. Treatment medications (dates unspecified) included: diphenhydramine hydrochloride. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from nausea, headache, and fever on 20-MAR-2021, and had not recovered from rash all over body and face. This report was non-serious.
Received Menactra vaccine on 8/12/2008.  The next day had fever (103 degrees F) and generalized body aches for three days.  On 09/07/2008 she had another fever and had two generalized convulsive seizures.  She was taken to the Emergency Room by ambulance.  Fever of unknown etilogy at that time.
Pt recvd 3 doses of Engerix-B & did not respond; 8JAN92 recvd a 4th dose of Engerix-B; 13FEB92 converted;
Elevated heart rate and blood pressure for 2 days starting on day 2. Slight shaking as a result. Muscle pain from day 1-3
feeling high; This spontaneous case was reported by a consumer and describes the occurrence of EUPHORIC MOOD (feeling high) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced EUPHORIC MOOD (feeling high). At the time of the report, EUPHORIC MOOD (feeling high) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. Treatment information was unknown.  Patient was in the age group of 40-50 years.
1st 1/9/21 1320 2nd 2/6/21 1320 ringing ears , cant sleep  tinnitius has lessened but isn't completely gone. took a Acetaminophen PM to help go to bed and meditate.
Swollen Lymph nodes under right arm showed up in my mammogram 9 days after the vaccine; This is a spontaneous report from a non-contactable consumer or other non-healthcare professional.   A 65-years-old female patient received bnt162b2 (BNT162B2, Batch/Lot Number: el3247) via an unspecified route of administration in right arm on 30Jan2021 at 09:00 as first dose single for covid-19 immunisation.  Medical history included sjogren's syndrome, autoimmune thyroiditis, hypersensitivity, seasonal allergy, allergy to plants and aloe allergy. Concomitant medications included estradiol, norethisterone acetate (COMBIPATCH), levothyroxine (LEVOTHYROXINE) and ciclosporin (RESTASIS). It was reported that the patient didn't take any vaccine within 4 weeks and did not have covid test positive prior to vaccination. The patient experienced swollen lymph nodes under right arm showed up in mammogram 9 days after the vaccine administration. Laboratory tests included mammogram which showed swollen lymph nodes under right arm. Outcome of the event was unknown.  No follow-up attempts are possible. No further information is expected.
pt recvd vax & exp antigenemia; No further details are available; Thic case is considered to be invalid;